We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BRBY:LSEBurberry Group plc Analysis

Data as of 2026-06-20 - not real-time

£1,134.50

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Burberry is trading well below its discounted cash‑flow implied fair value, suggesting a pricing gap despite a trailing P/E that is extremely high and profit margins that are thin. The recent earnings report disappointed investors, triggering a sharp slide in the share price and reinforcing a bearish technical bias, although the MACD histogram has turned positive and the RSI hovers around the midpoint, hinting at a possible short‑term bounce. Volume is on the rise, which could support a reversal if buying interest picks up, but the company’s balance sheet remains heavily leveraged with debt far exceeding equity, and revenue growth is barely perceptible.
Overall, the stock appears fairly valued when considering its intrinsic valuation versus earnings multiples, and it leans more toward a value play given the modest growth outlook. There is no dividend to speak of, and the mix of sector cyclicality, global exposure, and currency sensitivities adds layers of risk. Investors should weigh the upside potential against the high leverage and recent earnings weakness when forming a position.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Bearish technical trend with price near recent support
  • Earnings disappointment driving recent price weakness
  • High leverage limiting short‑term upside

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF model indicates a meaningful upside potential
  • Brand strength and global footprint support recovery
  • Forward earnings multiple appears reasonable

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Sustainable brand equity in the luxury segment
  • Elevated debt levels constrain long‑term flexibility
  • Cyclical consumer exposure and modest growth prospects

Key Metrics & Analysis

Financial Health

Revenue Growth0.90%
Profit Margin0.87%
P/E Ratio189.1
ROE2.14%
ROA3.07%
Debt/Equity160.99
P/B Ratio4.3
Op. Cash Flow£484.0M
Free Cash Flow£400.8M

Technical Analysis

TrendBearish
RSI48.9
Support£1,076.00
Resistance£1,215.00
MA 20£1,143.15
MA 50£1,149.77
MA 200£1,174.57
MACDBullish
VolumeIncreasing
Fear & Greed Index91.46

Valuation

Fair Value£1,289.61
Target Price£1,299.19
Upside/Downside14.52%
GradeFair
TypeValue

Risk Assessment

Beta0.56
Volatility38.16%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.